Search research articles
Contact Us
Filters
Showing results (91-100 of 149) with videos related to
Page
of 15
Sort By:
Journal of the National Cancer Institute
|
April 19, 1995
Prediction of carboplatin clearance from standard morphological and biological patient characteristics
E Chatelut, P Canal, V Brunner, et al.
International Journal of Cancer
|
November 11, 1992
Transforming growth factor beta 1 (TGF-beta 1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors
S Jozan, M Guerrin, P Mazars, et al.
Bulletin Du Cancer
|
September 8, 1999
[Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study]
L Gladieff, E Chatelut, M H Gaspard, et al.
International Journal of Cancer
|
May 29, 1995
Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell lines
A Nehmé, N Albin, M J Caliaro, et al.
Bulletin Du Cancer
|
January 1, 1983
[Cancer of the rectum: preoperative radiotherapy (344 cases)]
P F Combes, J Gary-Bobo, A Naja, et al.
La Nouvelle Presse Medicale
|
February 14, 1976
[The half-life of iodine 131-labelled fibrinogen in cancer patients. Effects of heparin]
A Boneu, J P Armand, A Blasco, et al.
Bulletin Du Cancer
|
March 6, 1999
[Compassionate use of gemcitabine in advanced pancreatic cancer: a French multicentric study]
J E Kurtz, V Trillet-Lenoir, R Bugat, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
300 mg/m2 carboplatin (Cb), adriamycin (A) cyclophosphamide (C) (CACb-300) combination in advanced ovarian carcinoma: a feasibility study
P Martin, R Bugat, G Pinon, et al.
European Journal of Clinical Pharmacology
|
January 1, 1991
Chronopharmacokinetics of doxorubicin in patients with breast cancer
P Canal, A Sqall, M de Forni, et al.
European Journal of Cancer & Clinical Oncology
|
March 1, 1989
Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients
R Bugat, J Robert, A Herrera, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 149) with videos related to
Sort By:
Page
of 15
Journal of the National Cancer Institute
|
April 19, 1995
Prediction of carboplatin clearance from standard morphological and biological patient characteristics
E Chatelut, P Canal, V Brunner, et al.
International Journal of Cancer
|
November 11, 1992
Transforming growth factor beta 1 (TGF-beta 1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors
S Jozan, M Guerrin, P Mazars, et al.
Bulletin Du Cancer
|
September 8, 1999
[Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study]
L Gladieff, E Chatelut, M H Gaspard, et al.
International Journal of Cancer
|
May 29, 1995
Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell lines
A Nehmé, N Albin, M J Caliaro, et al.
Bulletin Du Cancer
|
January 1, 1983
[Cancer of the rectum: preoperative radiotherapy (344 cases)]
P F Combes, J Gary-Bobo, A Naja, et al.
La Nouvelle Presse Medicale
|
February 14, 1976
[The half-life of iodine 131-labelled fibrinogen in cancer patients. Effects of heparin]
A Boneu, J P Armand, A Blasco, et al.
Bulletin Du Cancer
|
March 6, 1999
[Compassionate use of gemcitabine in advanced pancreatic cancer: a French multicentric study]
J E Kurtz, V Trillet-Lenoir, R Bugat, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
300 mg/m2 carboplatin (Cb), adriamycin (A) cyclophosphamide (C) (CACb-300) combination in advanced ovarian carcinoma: a feasibility study
P Martin, R Bugat, G Pinon, et al.
European Journal of Clinical Pharmacology
|
January 1, 1991
Chronopharmacokinetics of doxorubicin in patients with breast cancer
P Canal, A Sqall, M de Forni, et al.
European Journal of Cancer & Clinical Oncology
|
March 1, 1989
Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients
R Bugat, J Robert, A Herrera, et al.
Page
of 15